Mitigation of Total Body Irradiation-Induced Mortality and Hematopoietic Injury of Mice by a Thrombopoietin Mimetic (JNJ-26366821)

doi:10.21203/rs.3.rs-1132846/v1

Download PDF

Research Article

Mitigation of Total Body Irradiation-Induced Mortality and Hematopoietic Injury of Mice by a Thrombopoietin Mimetic (JNJ-26366821)

https://doi.org/10.21203/rs.3.rs-1132846/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 03 Mar, 2022

Read the published version in Scientific Reports →

You are reading this latest preprint version

The threat of a nuclear attack has increased in recent years highlighting the benefit of developing additional therapies for the treatment of victims suffering from Acute Radiation Syndrome (ARS). In this work, we evaluated the impact of a PEGylated thrombopoietin mimetic peptide, JNJ-26366821, on the mortality and hematopoietic effects associated with ARS in mice exposed to lethal doses of total body irradiation (TBI). JNJ-26366821 was efficacious as a mitigator of mortality and thrombocytopenia associated with ARS in both CD2F1 and C57BL/6 mice exposed to TBI from a cobalt-60 gamma-ray source. Single administration of doses ranging from 0.3 to 1 mg/kg, given 4, 8, 12 or 24 hours post-TBI (LD70 dose) increased survival by 30 – 90% as compared to saline control treatment. At the conclusion of the 30-day study, significant increases in bone marrow colony forming units and megakaryocytes were observed in animals administered JNJ-26366821 compared to those administered saline. In addition, enhanced recovery of FLT3-L levels was observed in JNJ-26366821-treated animals. Probit analysis of survival in the JNJ-26366821- and saline-treated cohorts revealed a dose reduction factor of 1.113 and significant increases in survival for up to 6 months following irradiation. These results support the potential use of JNJ-26366821 as a medical countermeasure for treatment of acute TBI exposure in case of a radiological/nuclear event when administered from 4 to 24 hours post-TBI.

Drug Discovery, Design, & Development

Molecular Biology

nuclear attack

Acute Radiation Syndrome

JNJ-26366821

body irradiation

Risk of radiation exposure due to terrorist attacks or nuclear accidents is increasing and it is critical to have multiple radiation countermeasures readily available. The extent of injury resulting from exposure to ionizing radiation is dependent on the extent of exposure, with the hematopoietic system being the most susceptible ¹. Development of radiation countermeasures for treatment of Hematopoietic Acute Radiation Syndrome (H-ARS) has focused on drugs that promote hematopoietic recovery and more specifically, agents that stimulate production of white cells and platelets following Total Body Irradiation (TBI)^2,3.

To date, the FDA has approved 4 radiation countermeasures for the mitigation of H-ARS, each serving to stimulate white cells or platelets: Neupogen® ⁴, Neulasta® ⁵, Leukine® ⁶, and Nplate® ⁷. Neupogen® (filgrastim) and Neulasta® (PEGylated filgrastim) were approved in 2015 and are both recombinant forms of the cytokine, Granulocyte-colony stimulating factor (G-CSF). Neupogen® (filgrastim) requires daily dosing until neutrophil counts are above 1000/ml for 3 consecutive readings and Neulasta® (PEGylated filgrastim) requires two doses administered a week apart. Both Neupogen and Neulasta mitigate H-ARS by facilitating bone marrow recovery (especially neutrophil recovery) which aids in maintaining immune function and capacity for fighting infections. Leukine® was approved in 2018 and is a recombinant form of the Granulocyte-macrophage colony-stimulating factor (GM-CSF) cytokine. Leukine promotes proliferation of various cell types including macrophages and eosinophils and requires daily dosing. Nplate® (romiplostim) is a thrombopoietin (TPO) mimetic IgG conjugated peptide with no sequence homology to endogenous TPO that stimulates platelet production. It was approved in 2021 to treat ARS based on data showing enhanced survival and platelet recovery in preclinical models of ARS^8,9.

Romiplostim is one of the four TPO mimetics that have been developed and approved for thrombocytopenia-related indications^10,11 and is the only one approved for ARS treatment. Interest in evaluating TPO mimetics for treatment of ARS was spurred by findings that recombinant human TPO enhanced survival and platelet recovery ¹². However, generation of autoantibodies to endogenous TPO was reported in some patients treated with recombinant human TPO ¹³, highlighting the need for TPO mimetics. JNJ-26366821 (TPOm) is a novel TPO mimetic that, like the approved TPO mimetics, has no sequence homology to endogenous TPO, mitigating the risk for generation of autoantibodies to endogenous TPO and subsequent thrombocytopenia. Like romiplostim, JNJ-26366821 is a synthetic peptide that can be administered subcutaneously or intravenously, whereas the other TPO mimetics are orally administered small molecules. JNJ-26366821 has a similar but distinct peptide sequence to romiplostim and is PEGylated to extend its half-life whereas romiplostim is IgG conjugated¹⁴. JNJ-26366821 has been evaluated in chronic toxicity studies ^15,16, in a Phase 1 study in healthy volunteers ¹⁶ and a Phase 1b study in cancer patients (internal results of Janssen). Given the unique properties of JNJ-26366821 and the need for multiple radiation countermeasures, it was of interest to evaluate the efficacy and safety of JNJ-26366821 in preclinical models of ARS.

Here, we present the effects of JNJ-26366821 on survival and hematopoietic recovery in mouse models of ARS when administered between four and twenty-four hours post-TBI. The results support future development of JNJ-26366821 as radiation mitigator.

JNJ-26366821 administered 4-24 hours post-TBI increases survival

Prior to TBI studies, TPOm (single dose of 3 mg/kg) was tested for safety and tolerability in CD2F1 male mice and was found to be safe at this dose with no abnormal clinical signs of toxicity and the absence of pathological findings on gross necropsy. JNJ-26366821 (0.3 mg/kg) or saline were administered 4 hours post-TBI at 9.35 Gy (LD70/30) and monitored for survival. At the conclusion of the study, 88% of animals administered JNJ-26366821 survived whereas 35% of animals administered saline survived (Figure 1A). Comparing the survival curves using Log-rank test demonstrated a significant difference (p=0.0002) between the saline and JNJ-26366821 curves; comparing the survival percentage in both groups at day 30 with a Fisher’s exact test (88% vs 35%) was also statistically significant (p=0.0001). Additional animals were administered either JNJ-26366821 (0.3 mg/kg or 1.0 mg/kg) or saline 24 hours post-TBI; survival in animals administered 1.0 mg/kg JNJ-2636682, 0.3 mg/kg JNJ-26366821, and saline was 79%, 71%, and 29%, respectively. (Figure 1B).

Log-rank test comparison of the survival curves demonstrated a significant increase in survival in both JNJ-26366821-treated groups over the saline-treated group (1.0 mg/kg JNJ-26366821 vs saline, p=0.0008 and 0.3 mg/kg JNJ-26366821 vs saline, p=0.0122); survival in JNJ-26366821 groups was not significantly different (p=0.4787). Comparison of survival outcome at day 30 (Fisher’s exact test), demonstrated significantly increased survival in both JNJ-26366821-treated groups over saline (1.0 mg/kg JNJ-26366821 (79%) vs saline (29%), p=0.0012 and 0.3mg/kg JNJ-26366821 (71%) vs saline (29%), p=0.0087); and no significant difference in survival outcome between the two JNJ-26366821-treated groups (79% vs 71%, p=0.7400). Additionally, survival following multiple doses of JNJ-26366821 (a 1, 2, or 3 dose regimen administered once daily) was assessed however, no additional survival benefit was observed in animals administered more than a single dose of JNJ-26366821 (Supplemental Figure 1).

JNJ-26366821 dose-dependently enhances survival post-TBI

Male CD2F1 mice were irradiated at 9.75 Gy and administered saline or JNJ-26366821 at various concentrations (0.1, 0.3, 1.0, and 3.0 mg/kg). The highest survival was observed in animals administered 1.0 mg/kg JNJ-26366821 (88%), followed by 63%, 54%, 42%, and 21% survival in animals administered 0.3 mg/kg JNJ-26366821, 3.0 mg/kg JNJ-26366821, 0.1 mg/kg JNJ-26366821, and saline, respectively (Figure 2A). Log-rank comparison of the survival curves show statistical differences between treatment with 0.3 mg/kg and 1.0 mg/kg JNJ-26366821 (p=0.0106 and p<0.0001, respectively); survival in animals treated with 0.1 mg/kg and 3.0 mg/kg JNJ-26366821 was not statistically different than that in saline-treated animals (Log-rank p=0.2515 and p=0.0734, respectively). When comparing the survival curves (Log-rank test) for the various JNJ-26366821-treated groups, survival in the groups that received 0.1 mg/kg and 1.0 mg/kg were statistically different (p=0.0009), whereas survival curves for animals administered 0.1 and 0.3 or 0.1 and 3.0 mg/kg were not statistically different (p=0.1599 and p=0.3606, respectively). Survival curves for animals that received 0.3 and 1.0 mg/kg were statistically different (p=0.0451) whereas survival curves from animals receiving 0.3 and 3.0 mg/kg were not (p=0.5674). Finally, survival curves for animals administered 1.0 mg/kg were statistically different from those administered 3.0 mg/kg (p=0.0096). All log-rank statistical analyses are summarized in Table 1 (top set of values). In total, the group that was administered 1.0 mg/kg JNJ-26366821 was the only group was statistically different from all other groups.

Comparing the 30-day survival (Fisher’s exact test) of animals administered saline or JNJ-26366821, survival was significantly increased in animals administered 0.3 mg/kg, 1.0 mg/kg, and 3.0 mg/kg JNJ-26366821 over the saline control (p=0.0077, p<0.0001, and p=0.0355 respectively) no statistical difference was observed in the survival of animals administered 0.1mg/kg JNJ-26366821 as compared to saline (p=0.2124). Comparison of 30-day survival (Fisher’s exact test) in the various JNJ-26366821 dose groups showed survival for animals administered 0.1 mg/kg was lower than animals administered 1.0 mg/kg JNJ-26366821 (p=0.0020), whereas survival for animals administered 0.1 and 0.3 or 0.1 and 3.0 mg/kg JNJ-26366821 was not statistically different from one another (p=0.2476 and p=0.5639, respectively). Survival for animals that received 0.3 and 1.0 mg/kg or 0.3 and 3.0 mg/kg were not statistically different from one another (p=0.0933 and p=0.7702, respectively). Finally, survival curves for animals administered 1.0 mg/kg were statistically different from those administered 3.0 mg/kg (p=0.0243).

Table 1

Comparison of Log-Rank (top) and Fisher’s exact test (bottom) statistical analyses for Figure 2A.
Group	Saline	0.1mg/kg JNJ-26366821	0.3mg/kg JNJ-26366821	1.0 mg/kg JNJ26366821	3.0 mg/kg JNJ-26366821
Saline	-	p=0.2515	p=0.0106	p<0.0001	p=0.0734
0.1mg/kg JNJ-26366821	p=0.2124	-	p=0.1599	p=0.0009	p=0.3606
0.3mg/kg JNJ-26366821	p=0.0077	p=0.2476	-	p=0.0451	p=0.5674
1.0 mg/kg JNJ26366821	p<0.0001	p=0.0020	p=0.0933	-	p=0.0096
3.0 mg/kg JNJ-26366821	p=0.0355	p=0.5639	p=0.7702	p=0.0243	-

Above the diagonal of non-comparison where groups would be compared with themselves are significance values for log-rank analysis of the survival curves. Below the diagonal are significance values for Fisher’s exact test conducted based on surviving proportions on day 30.

Similar analyses were conducted for male CD2F1 mice administered saline or JNJ-26366821 (0.1, 0.3, 1.0, 2.0, and 3.0 mg/kg) 24 hours after TBI at 9.35 Gy. The highest survival was observed in animals administered 1.0 mg/kg JNJ-26366821 (63%), followed 58%, 50%, 46%, and 33% survival in animals administered 0.1 and 0.3 mg/kg JNJ-26366821, 2.0 mg/kg JNJ-26366821, 3.0 mg/kg JNJ-26366821 and saline, respectively (Figure 2B). These data indicated the optimal JNJ-26366821 dose was 1.0mg/kg however the modest separation in survival between saline and the various doses of JNJ-26366821 did not result in statistical significance. Comparing the groups administered saline and 1.0mg/kg JNJ-26366821 (lowest and highest survival, respectively), the Log-rank test (p=0.1402) and Fisher’s exact test at day 30 (p=0.0820) were the closest to statistical significance.

JNJ-26366821 enhances survival up to 24 hours post-TBI

To evaluate the impact of time of administration at the maximally effective dose of 1.0 mg/kg JNJ-26366821, male CD2F1 mice were irradiated at 9.75 Gy (Figure 2C) and JNJ-26366821 and administered JNJ-26366821 or saline at 4, 8, and 12 hours post-TBI. Survival in animals administered JNJ-26366821 or saline 4 hours post-TBI was 80% and 20% respectively; a log-rank test comparing the curves showed significant difference (p=0.0006) and a Fisher’s exact test comparing survival at day 30 demonstrated a significant increase in survival in animals administered JNJ-26366821 (p=0.0004). For animals administered JNJ-26366821 or saline 8 hours post-TBI, survival was 90% and 10% respectively; log-rank comparison of the curves revealed significant difference (p<0.0001) and a Fisher’s exact test comparing survival at day 30 demonstrated a significant increase in survival in animals administered JNJ-26366821 (p<0.0001). Survival in animals administered JNJ-26366821 or saline 12 hours post-TBI was 70% and 20% respectively; the curves were significantly different as shown by log-rank test (p=0.0019) and a Fisher’s exact test comparing survival at day 30 showed a significant increase in survival in animals administered JNJ-26366821 (p=0.0036). Comparison of survival in the groups administered JNJ-26366821 did not reveal statistically significant difference, +4 h vs +8 h (Log-rank test: p=0.6392, 30 day Fisher’s exact test: p=0.6614), +4 h vs +12 h (Log-rank test: p=0.5074, 30 day Fisher’s exact test: p=0.7164), and +4 h vs +12 h (Log-rank test: p=0.6392, 30 day Fisher’s exact test: p=0.6614), +4 h vs +12 h (Log-rank test: p=0.1404, 30 day Fisher’s exact test: p=0.2351). Similarly, no significant differences were observed amongst the groups administered saline.

JNJ-26366821 administered 24 hours post-TBI enhances recovery of neutrophils, platelets, and bone marrow progenitor cells

A 1.0 mg/kg dose of JNJ-26366821 or saline was administered to CD2F1 mice 24 hours post-TBI with a nonlethal dose (7 Gy). Blood was collected at various time points in the 30-day study; blood was also collected at the same time points from an additional cohort of animals that were not exposed to irradiation but received 1.0 mg/kg JNJ-26366821 or saline. Amongst the non-irradiated animals (blue traces, Figure 3A), JNJ-26366821 administration was sufficient to increase neutrophil counts on day 3 (2.931±1.376 x10³cells/µl of blood for animals administered JNJ-26366821 vs. 0.553±0.348 x10³cells/µl of blood for animals administered saline, p=0.0001). Amongst irradiated animals (green traces, Figure 3A), neutrophil counts were elevated in animals administered JNJ-26366821 compared to those administered saline 24 hours post-TBI on days 10 and 14 (day 10: 0.094±0.040 x10³cells/µl of blood for animals administered JNJ-26366821 vs. 0.045±0.024 x10³cells/µl of blood for animals administered saline, p=0.0040 and day14: 0.477±0.223 x10³cells/µl of blood for animals administered JNJ-26366821 vs. 0.137±0.085 x10³cells/µl of blood for animals administered saline, p=0.0003).

In the non-irradiated animals (blue traces, Figure 3B), JNJ-26366821 elevated platelet counts compared to saline on days 3, 7, and 10 (day 3: 1201 ± 269 x10³cells/µl vs 422 ± 300 x10³cells/µl, p<0.0001, day 7: 1201 ± 269 x10³cells/µl vs 422 ± 300 x10³cells/µl, p=0.0002, and day 10: 1201 ± 269 x10³cells/µl vs 422±300 x10³cells/µl, p<0.0001). In the irradiated animals (green traces, Figure 3B), JNJ-26366821 accelerated recovery of platelet counts compared to saline on days 10 and 14 (day 10: 176 ± 76 x10³cells/µl vs 41 ± 10 x10³cells/µl, p<0.0001 and day 14: 478 ± 113 x10³cells/µl vs 106 ± 40 x10³cells/µl, p<0.0001). Taken together, these results demonstrate an accelerated recovery of these cell types in animals administered 1.0 mg/kg JNJ-26366821 24 hours post-TBI. Additional cell types were also analyzed including white blood cells, monocytes, and lymphocytes (Supplemental Figures 2A-C). These measurements showed these three cell types were elevated in non-irradiated animals administered JNJ-26366821 compared to those administered saline on day 3 and all three cell types were elevated in irradiated animals administered JNJ-26366821 compared to those administered saline on day 14.

At the conclusion of the 30-day study, bone marrow was collected from the same animals and assayed for colony forming units (Figure 3C). Total bone marrow colony forming units (CFU-GM, CFU-GEMM, CFU-E, and BFU-E) in the non-irradiated animals were elevated in animals administered JNJ-26366821 (1.0 mg/kg) compared to those administered saline (30.3 ± 5.3 colonies vs 15.0 ± 8.2 colonies, p=0.0440). Similarly, bone marrow colony forming units in the irradiated animals were elevated in animals administered JNJ-26366821 compared to those administered saline (41.5 ± 7.3 colonies vs 12.5 ± 7.2 colonies, p=0.0010).

JNJ-26366821 enhances survival and hematopoietic recovery in an additional mouse strain

The increased survival efficacy of JNJ-26366821 treatment in irradiated CD2F1 mice was confirmed using the C57BL/6 strain. C57BL/6 male mice were exposed to 8.0 Gy (TBI) and administered 1.0 mg/kg JNJ-26366821 24 hours post-TBI (Figure 4A). Survival in animals administered JNJ-26366821 was 83% whereas survival in the saline-treated animals was 13%; a log-rank test confirmed the survival curves were statistically different from one another (p<0.0001) and a Fisher’s exact test revealed survival was statistically higher in the animals administered JNJ-26366821 (p<0.0001).

At the conclusion of the 30-day study, blood, femoral bone marrow, and sterna were collected from C57BL/6 animals in the survival study (Figure 4A) which included those administered either saline or 1.0 mg/kg JNJ-26366821 24 hours post-TBI at 8.0 Gy as well as age matched, non-irradiated naïve animals. Complete blood cell counts were assessed in whole blood (Figure 4B). White blood cells counts were highest in naïve animals (10.2 ± 2.3 x10³ cells/µl) and were significantly higher in the naïve group than in either irradiated group (saline 0.72 ± 0.38 x10³ cells/µl, p=0.0164 and JNJ-26366821 1.8 ± 1.0 x10³ cells/µl, p=0.0042); there was no statistical difference between the counts in the irradiated groups (p=0.1553). Neutrophil counts were also highest in naïve animals (0.95 ± 0.36 x10³ cells/µl) and higher in the naïve group than either irradiated group, although not significantly (saline 0.303 ± 0.291 x10³ cells/µL, p=0.0707 and JNJ-26366821 0.723 ± 0.224 x10³ cells/µl, p=0.3955). Additionally, the counts in the irradiated groups were not statistically different from one another (p=0.1188). Lymphocytes counts were highest in naïve animals (9.0 ± 1.8 x10³ cells/µl) and significantly higher in the naïve group than either irradiated group (saline 0.33 ± 0.04 x10³ cells/µl, p=0.0148 and JNJ-26366821 0.72 ± 0.22 x10³ cells/µl, p=0.0023); the counts in the irradiated groups were not statistically different from one another (p=0.5157). For red blood cells, counts were not statistically higher in naïve animals (10.6 ± 0.3 x10⁶ cells/µl) as compared to animals administered saline (5.2 ± 2.5 x10⁶ cells/µl, p= 0.0652) however naïve counts were higher than counts in animals administered JNJ-26366821 (8.3 ± 0.7 x10⁶ cells/µl, p=0.0058); no significant difference was observed between counts in the irradiated groups (p=0.1080). Finally, the highest platelet counts were observed in naïve animals (1364 ± 170 x10³ cells/µl) and counts in naïve group were significantly higher than counts in either irradiated group (saline 209 ± 86 x10³ cells/µl, p=0.0020 and JNJ-26366821 463 ± 189 x10³ cells/µl, p=0.0036); the counts in irradiated groups were not statistically different from one another (p=0.1011). For all cell type counts, the prevailing trend was naïve>JNJ-26366821>saline.

Analysis of the total colony forming units (CFU-GM, CFU-GEMM, CFU-E, and BFU-E) in the bone marrow of these animals (Figure 4C) demonstrated highest counts in naïve animals (20.5 ± 3.1) that were significantly elevated relative to animals administered saline (0.25 ± 0.50, p=0.0006) or JNJ-26366821 (7.8 ± 2.6, p=0.0150). CFU counts were also higher in animals administered JNJ-26366821 over those in animals administered saline (p=0.0109). Similarly, megakaryocytes counts (Figure 4D) in H&E stained sternum were highest in naïve animals (41.0 ± 10.6) and were significantly elevated relative to those in animals administered saline (10.0 ± 6.9, p=0.0132) but not those administered JNJ-26366821 (25.7 ± 6.4, p=0.0986). Additionally, counts were higher in animals administered JNJ-26366821 than animals administered saline (p=0.0454). Finally, circulating FLT3-L, as assessed by ELISA in serum(Figure 4E), was significantly higher in the saline (4065 ± 1800 pg/ml) group as compared to both the naïve group (368 ± 21 pg/ml, p=0.0236) and JNJ-26366821 group (1114 ± 191 pg/ml, p=0.0476); FLT3-L levels were elevated in animals administered JNJ-26366821 as compared to naïve levels (p=0.0025).

JNJ-26366821 has a favorable dose reduction factor and enhances long term survival of C57BL/6 male mice

Male C57BL/6 mice were administered saline or JNJ-26366821 (1.0 mg/kg) 24 hours after TBI at various radiation doses to determine the dose reduction factor (Figure 5A). By plotting survival for the various radiation dose groups treated with either saline or JNJ-26366821, the dose of radiation correlating to 50% lethality over 30 days (LD50/30) was determined by probit analysis. For animals administered saline, the LD50/30 dose was 7.78 Gy (95% confidence interval: 7.65-7.90 Gy) and for animals administered JNJ-26366821 the LD50/30 dose was 8.65 Gy (95% confidence interval: 8.52-8.79 Gy). In conjunction, these values indicated a dose reduction factor of 1.113 (95% confidence interval: 1.063-1.197). From this study, survival of animals irradiated at 8.0 and 8.5 Gy was monitored for 6 months (Figures 5B and 5C, respectively). Analysis of the survival curves for animals irradiated at 8.0 Gy indicated the curves were significantly different between saline and JNJ-2636682-treated groups as determined by by log-rank test (p<0.0001) and that survival was significantly higher at 6 months in animals administered JNJ-26366821 compared to those administered saline (94.7% vs 14.3%, p<0.0001). Analysis of the survival curves for animals irradiated at 8.5 Gy indicated the curves were significantly different between saline and JNJ-2636682-treated groups as determined by log-rank test (p=0.0003) and that survival was significantly higher at 6 months in animals administered JNJ-26366821 compared to those administered saline (52.6% vs 0%, p<0.0001).

Based on its favorable safety and tolerability profile in animals ¹⁵ and humans ¹⁶, we evaluated the potential of JNJ-26366821 to enhance survival and hematopoietic recovery in preclinical mouse models of ARS. A single dose of TPOm administered either 4, 8, 12, or 24 hours post-TBI enhanced 30-day survival significantly. In contrast, a single dose of recombinant human TPO (rhTPO) administered either 2 hours before or 2 hours after TBI increased 30-day survival however, no efficacy was observed when administration was delayed to 24 hours post-TBI ¹⁷. In addition, JNJ-26366821 is effective in multiple strains of mice, suggesting its use in diverse populations. Multiple dosing with JNJ-26366821 in our irradiated mouse model did not show additional benefit over a single administration 24 hours post-TBI.

It is known that radiation-induced neutropenia and thrombocytopenia contribute significantly to lethality as a result of damage to the progenitor cells in the bone marrow^18–20. To test the hypothesis that JNJ-26366821 increases thrombopoiesis in irradiated animals, which may partly contribute to survival benefit, we analyzed circulation peripheral blood cells in non-lethally irradiated (7 Gy) mice at 8 time points throughout the 30-day period following irradiation. This dose of radiation in the CD2F1 strain has been shown to induce severe bone marrow myelosuppression without associated mortality²¹. Since blood was collected through submandibular vein (only 20 µl) without sacrificing the animals, this model allows for longer sampling times with surviving irradiated controls. The increase in circulating platelets by JNJ-26366821 supports our hypothesis that improvement in survival after JNJ-26366821 administration may be partly due to the thrombopoietic nature of the drug. The increased neutrophil counts observed after JNJ-26366821 administration may be due to stem cell mobilization into peripheral blood. Since JNJ-26366821 is shown to function by interaction through cMpl receptor, the drug’s ability to rescue mice from radiation-induced lethality could be attributed to stimulation of bone marrow to promote faster recovery of progenitor cells^22–24. In addition, the effect of JNJ-26366821 in protection of vasculature integrity may have also contributed to the survival benefit²⁵.

There are data showing that patients who switched between romiplostim or the FDA approved TPO mimetic eltrombopag, either due to lack of efficacy or for other reasons such as adverse side effects, had a significant clinical benefit from the second drug compared to the one that was taken initially ^9,26−30. These results support the potential value of developing additional novel TPO agonists, even though Romiplostim and Eltromboag have already been approved for use in humans.

In conclusion, the current study reports the first evaluations of JNJ-26366821 as a radiation mitigator in mice. The results demonstrate a single dose of JNJ-26366821 provides a significant survival benefit in lethally irradiated mice, with a window of protection from 4 to 24 h post-TBI and potentially beyond. Administration of JNJ-26366821 also mitigates platelet loss and enhances the rate of platelet and neutrophil recovery in CD2F1 mice. Confirmation of efficacy was conducted in male C57BL/6 male mice as seen by observation of trends towards increased recovery of peripheral blood cell counts at the conclusion of the 30-day study, significant increases in colony forming units and megakaryocytes in animals administered JNJ-26366821 compared to those administered saline, and recovery of FLT3-L levels in animals administered JNJ-26366821. Probit analysis of survival in animals administered JNJ-26366821 or saline revealed a dose reduction factor of 1.113 and animals exposed to lethal radiation doses showed significant increases in survival up to 6 months following irradiation and subsequent administration of JNJ-26366821 compared to animals administered saline after irradiation. Taken together, these results demonstrate increased survival and recovery with JNJ-26366821-treatment following exposure to ionizing radiation highlighting the promise of JNJ-26366821 as a radiation countermeasure.

Animals

Male CD2F1 mice (10 – 11 weeks old) were purchased from Envigo (Indianapolis, Indiana) and male C57BL/6 mice (10 – 11 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME). The mice were housed in the Armed Forces Radiobiology Research Institute’s (AFRRI) vivarium (accredited by the Association for Assessment and Accreditation of Laboratory Animal Care-International). Experimental animals were identified by tail tattoo and housed 4 per box in sterile polycarbonate boxes with filter covers (Microisolator, Lab Products Inc., Seaford, DE) with autoclaved hardwood chip bedding. The animals received Harlan Teklad Rodent Diet 8604 and acidified water (pH 2.5 – 3.0) ad libitum and were acclimatized for 1- 2 weeks prior to the start of each study. The animal rooms were maintained at 21 ± 2°C and 50 ± 10% relative humidity with 10–15 cycles of fresh air hourly and a 12:12 hour light:dark cycle. All procedures pertaining to animals were reviewed and approved by the AFRRI Institutional Animal Care and Use Committee (IACUC) using the principles outlined in the National Research Council’s Guide for the Care and Use of Laboratory Animals and performed in accordance with relevant guidelines and regulations. Animal studies were conducted in compliance with ARRIVE guidelines.

Drug and drug preparation

JNJ-26366821 is a novel PEGylated TPO mimetic peptide developed by Janssen Research & Development, LLC. (Raritan, NJ). JNJ-26366821 consists of two identical 14 amino acid peptide chains of 3,295 Daltons connected by a lysine residue and linked at each N-terminal to a polyethylene glycol (PEG) chain of 20,000 Daltons. JNJ-26366821 was supplied to AFRRI in a powder form and was formulated in normal sterile saline (0.9% NaCl) before use and protected from light. Either drug or its vehicle was injected subcutaneously (SC) at the nape of the neck, post-TBI at the time indicated for each study.

Total Body Irradiation (TBI) Studies

Since clinical trials in which humans are exposed to lethal doses of TBI cannot ethically be conducted, the approval process for radiation countermeasures is governed by guidance issued by the FDA known as the Animal Rule ³¹. Under this guidance, preclinical data in one or more species along with safety and dosing data in humans is used to support the approval of drugs for use in this indication. The mouse is an accepted model for development of radiation countermeasures and it was therefore used to evaluate JNJ-26366821.

Mice were irradiated bilaterally at an estimated dose rate of ~0.6 Gy/min in the Cobalt-60 γ-irradiation facility at AFRRI (Bethesda, MD). Animals were placed in well-ventilated plexiglass chambers made specifically for irradiating mice. An alanine/Electron Spin Resonance (ESR) dosimetry system (American Society for Testing and Material Standard E 1607) was used to measure the dose rates in the cores of acrylic phantoms (3 inches long and 1 inch in diameter) located in all empty slots of the exposure rack in the plexiglass chamber. ESR signals were measured with a calibration curve based on standard calibration dosimeters provided by the National Institute of Standard and Technology (Gaithersburg, MD). The calibration curve was verified by inter-comparison with the National Physical Laboratory in the United Kingdom. The corrections applied to the measured dose rates in phantoms were for decay of the Co-60 source and for a small difference in mass-energy absorption coefficients for water and soft tissue at the Co-60 energy level. The radiation field was previously reported to be uniform within ±2% ^19,32.

Housing and care of animals after irradiation

After irradiation, animals were returned to their cages and monitored three to four times daily (early morning, late morning, late afternoon and evening). Sick animals were monitored closely and a health score was given at each time of monitoring in accordance with pre-defined criteria described and approved in the IACUC protocol. A predetermined health score that necessitated euthanasia was also approved in the IACUC protocol; mice that reached this threshold health score were humanely euthanized. Pain and distress were monitored using several criteria including unresponsiveness, abnormal posture, unkempt appearance, immobility, labored breathing, respiratory distress, and lack of coordination. A mouse exhibiting any of the following symptoms was determined to be moribund and was euthanized: inability of the mouse to right itself, limb paralysis, abdominal breathing, a constant twitching, trembling, or tremor that lasted for more than 10 seconds, or greater than 35% weight loss as per IACUC policy. Animals were euthanized according to American Veterinary Medical Association (AVMA) guidelines.

Survival studies with JNJ-26366821 in CD2F1 and C57/BL6 mice

The survival studies in CD2F1 male mice evaluated JNJ-23666821 treatment (SC) (0.3 mg or 1 mg/kg) 24 hours post-TBI and JNJ-26366821 treatment (0.3 mg/kg) 4 hours post-TBI. Each treatment group for drug and its vehicle (saline) contained 24 animals and the radiation dose for both studies was 9.35 Gy (~LD70/30, 70% mortality over 30-day period). The efficacy of JNJ-26366821 as a radiation mitigator against morbidity and mortality was then further confirmed in C57BL/6 male mice. The C57BL/6 mice were administered 1 mg/kg JNJ-26366821 24 hours post-TBI (8.0 Gy, ~LD70/30) in the same manner as the CD2F1 mice. Mice in all studies were weighed prior to start of the study, animals outside ±10% of the mean weight were excluded, and selected mice were randomized into groups of four animals per box. Survival was monitored up to four times a day when warranted for 30 days and surviving animals were euthanized at the completion of the observational period. Survival data was plotted as Kaplan-Meier plots and statistical significance of the survival differences was determined by log-rank and Fisher’s exact tests using GraphPad Prism 8 software.

Dose and time optimization study with JNJ-26366821 in CD2F1 male mice

Five dose levels of JNJ-26366821 (0.1, 0.3, 1.0, 2.0, 3.0 mg/kg) were selected to determine the optimum single dose of JNJ-26366821 to achieve maximum efficacy at 24 hours post-TBI in CD2F1 mice. Treatment and vehicle cohorts (n=24 mice/cohort) were irradiated at 9.35 Gy (~LD70/30) and subsequently administered one of the doses listed above or the equivalent volume of the vehicle. Another dose optimization study was conducted at 4 hours post-TBI with treatment and vehicle cohorts (n=24 mice/cohort) exposed to 9.75 Gy (~LD 90/30). Here, 4 different doses of JNJ-26366821 (0.1, 0.3, 1.0, and 3.0 mg/kg) were tested.

After determining the optimal dose of 1.0 mg/kg in the above studies, a time optimization study was performed by administering JNJ-26366821 at different time points (4, 8 and 12 hours post-TBI). Six groups, three treatment groups and three time-matched vehicle groups (n=24 mice/group), were used in this study. Each group was irradiated at 9.75 Gy (~LD90/30) and administered the optimal dose of JNJ-26366821 (1.0 mg/kg) or vehicle (saline) at 4, 8, or 12 h post-TBI. Animals were monitored for 30 days in the same way as described previously for all survival studies.

Hematology studies with JNJ-26366821

To study the effects of JNJ-26366821 on recovery from hematopoietic injury following TBI, CD2F1 male mice (n=10/group) were treated with either JNJ-26366821 (1 mg/kg) or its vehicle (saline) 24 hours after TBI at a non-lethal dose of 7.0 Gy. A non-lethal dose was used to allow for animal survival while following the recovery from the hematopoietic injury that takes place following TBI. In addition, a group of sham-irradiated CD2F1 male mice were given either the drug or saline. Additionally, blood was collected from C57BL/6 male mice irradiated at an LD70/30 dose (8.0 Gy). Mice were anesthetized with isoflurane (Hospira Inc., Lake Forest, IL) and blood was collected from the submandibular vein using a 23 G needle at 2 hours and 1, 3, 7, 10, 14, and 21 days post-TBI. Mice were allowed to recover fully from anesthesia and monitored closely for any signs of a post-anesthesia reaction or bleeding at the collection site before being returned to group-housed cages. Approximately 20 µL of blood was collected into tubes containing EDTA and blood was continually rotated until CBC/differential analysis of white blood cell (WBC), absolute neutrophil (NEU), monocytes (MON), lymphocyte (LYM), and platelet (PLT) counts with the HESKA Element HT™ 5 Analyzer system (HESKA Corporation, Loveland, CO).

FLT3-L determination in serum by ELISA

Blood was collected from male C57BL/6 mice via cardiocentesis into Microtainer serum collection tubes (BD item #36596, Franklin Lakes, New Jersey) from animals anesthetized with isoflurane (5% induction, 2% maintenance); following blood collection animals were euthanized. Serum was collected following centrifugation for 10 minutes at 2400 x g. Circulating FLT3-L levels were determined by ELISA analysis (R&D Systems item#MFK00, Minneapolis, MN) performed according to the manufacturer’s instructions; serum was diluted 1:3.

Colony Forming Unit Assay from Femoral Bone Marrow

Following euthanasia, femurs were collected and the bone marrow was extracted by flushing with IMDM with 2% FBS then plated following protocols from the manufacturer (Mouse Colony-Forming Cell Assays Using MethoCult®, Stem Cell Technologies, Cambridge, MA). Cultures were incubated for 14 days after plating and Granulocyte-macrophage colony forming units (CFU-GM), granulocyte-erythrocyte-monocyte-macrophage CFU (CFU-GEMM), colony-forming unit-erythroid (CFU-E) and erythroid burst-forming units (BFU-E) were identified and quantified using a Nikon TS100F microscope. Fifty or more cells were considered one colony. Data are show as mean ± standard error of mean (SEM) and statistical significance was determined between irradiated vehicle-treated and drug-treated groups ³³.

Megakaryocytes from Sternal bone marrow

Also following euthanasia, sterna were collected on 30 days post-TBI. The sterna were fixed in a 20:1 volume of fixative (10% buffered formalin) to tissue then embedded in paraffin and longitudinal 5 µm sections were stained with regular hematoxylin and eosin (H&E) stain following standard protocol ³³. Megakaryocyte numbers were counted from each slide.

Determination of Dose Reduction Factor (DRF)/long term survival

Male C57BL/6 mice were distributed into one of twelve groups with 6 groups administered saline and 6 groups administered 1.0 mg/kg JNJ-26366821 24h after TBI. The groups that ultimately received saline were irradiated at the following doses: 7.5, 8.0, 8.5, 9.0, 9.5, and 10.0 Gy. The groups that ultimately received JNJ-26366821 were irradiated at the following doses: 8.0, 8.5, 9.0, 9.5, 10.0, and 10.5 Gy. Animals were monitored as mentioned above in the methods for the survival studies. Thirty days post-TBI, the survival in each radiation dose group was used for probit analysis (IBM SPSS Statistics 25.0) to determine the LD50/30 value for both saline or JNJ-26366821treatment ³⁴ to calculate the DRF. Surviving animals from the DRF studies were monitored for up to 6 months post-TBI to examine long term survival.

Statistical analysis

Survival data was plotted as Kaplan-Meier plots; GraphPad Prism 8 software was utilized to perform Fisher’s exact test to compare survival at 30 days and a log-rank test to compare survival curves. Probit analysis was conducted with IBM SPSS Statistics 25.0 and a student’s t-test was used to assess differences between groups. Averages were reported +/- standard error of the mean (SEM).

ACKNOWLEDGEMENT

The authors gratefully acknowledge Kefale Wuddie, Zemenu Aschenake, HM1 Paul O’Brien, and Fialka G. Ward for technical assistance. The authors also would like to thank Dr. Carmen Rios and Dr. Merriline Satyamitra for their contributions in the scientific discussion and intellectual input. Support for the work was provided by grants from the National Institute of Allergy and Infectious Diseases (AA112044-001-04000 to SG and 1U01AI133608-01 to SG), JPC-7 project DM178020, and the AFRRI Intramural funding RAB23338. The opinions contained herein are the private views of the authors, and are not necessarily those of Armed Forces Radiobiology Research Institute, the Uniformed Services of the University of the Health Sciences, or the Department of Defense.

CONFLICT OF INTEREST

The following authors (VPK, GPHH, SS, SB, NKS, BH, CD and SPG) declare no conflict of interest. MG and GE are employees of Johnson & Johnson and its subsidiary Janssen Pharmaceuticals is working on the development of JNJ-26366821 and stand to benefit financially from the successful development of the compound.

Author’s Contribution:

Conceived and designed the experiments: SPG, CD, VPK, GPHH, GE, MG. Performed the experiments: VPK, GPHH, SB, SS, BH, NKS, SPG. Analyzed the data: VPK, GPHH, BH, SB. Wrote the paper: GPHH, VPK, NKS, SPG, GE, MG, CD

Singh, V. K. & Seed, T. M. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. International Journal of Radiation Biology 93, 851-869, doi:10.1080/09553002.2017.1332438 (2017).
Singh, V. K., Romaine, P. L. & Seed, T. M. Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile. Health Phys 108, 607-630, doi:10.1097/hp.0000000000000279 (2015).
Singh, V. K. & Seed, T. M. Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond. International Journal of Radiation Biology 97, 1526-1547, doi:10.1080/09553002.2021.1969054 (2021).
Amgen Inc. Neupogen (filgrastim) injection for subcutaneous or intravenous use. (2015).
Amgen Inc. NEULASTA® (pegfilgrastim) injection, for subcutaneous use. (2015).
Sanofi-Aventis U.S. LLC. LEUKINE® (sargramostim) for injection, for subcutaneous or intravenous use. (2018).
Amgen Inc. NPLATE® (romiplostim) for injection, for subcutaneous use. (2021).
Kuter, D. J. The biology of thrombopoietin and thrombopoietin receptor agonists. International journal of hematology 98, 10-23, doi:10.1007/s12185-013-1382-0 (2013).
Rodeghiero, F. & Carli, G. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Ann Hematol, doi:10.1007/s00277-017-2953-6 (2017).
Andrea, L. D. et al. Medical Countermeasures for Platelet Regeneration after Radiation Exposure. Radiation research 176, doi:10.1667/RROL01.1 (2011).
Bunin, D. I. et al. Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice. International Journal of Radiation Biology 96, 145-154, doi:10.1080/09553002.2019.1605465 (2020).
Kelemen, E., Cserhati, I. & Tanos, B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 20, 350-355 (1958).
Kuter, D. J. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 60, 193-206, doi:10.1146/annurev.med.60.042307.181154 (2009).
Cwirla, S. E. et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276, 1696-1699 (1997).
Knight, E. et al. Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects. International journal of toxicology 30, 385-404, doi:10.1177/1091581811404708 (2011).
Liem-Moolenaar, M. et al. Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans. Clin Pharmacol Ther 84, 481-487 (2008).
Mouthon, M. A., Van der Meeren, A., Vandamme, M., Squiban, C. & Gaugler, M. H. Thrombopoietin protects mice from mortality and myelosuppression following high-dose irradiation: importance of time scheduling. Canadian journal of physiology and pharmacology 80, 717-721 (2002).
Ghosh, S. P. et al. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol 85, 598-606, doi:912684558 [pii] 10.1080/09553000902985128 (2009).
Ghosh, S. P. et al. Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice. Journal of radiation research 53, 526-536, doi:10.1093/jrr/rrs001 (2012).
Satyamitra, M. M. et al. Hematopoietic Recovery and Amelioration of Radiation-Induced Lethality by the Vitamin E Isoform delta-Tocotrienol. Radiation research 175, 736-745, doi:10.1667/RR2460.1 (2011).
Kulkarni, S. et al. Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. Radiation research 173, 738-747, doi:10.1667/RR1824.1 (2010).
Samtani, M. N., Perez-Ruixo, J. J., Brown, K. H., Cerneus, D. & Molloy, C. J. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects. Journal of clinical pharmacology 49, 336-350, doi:10.1177/0091270008329559 (2009).
Satyamitra, M. et al. A TPO receptor agonist, ALXN4100TPO, mitigates radiation-induced lethality and stimulates hematopoiesis in CD2F1 mice. Radiation research 175, 746-758, doi:10.1667/RR2462.1 (2011).
Mouthon, M. A. et al. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. International journal of radiation oncology, biology, physics 43, 867-875 (1999).
Mouthon, M. A. et al. Single administration of thrombopoietin to lethally irradiated mice prevents infectious and thrombotic events leading to mortality. Experimental hematology 29, 30-40 (2001).
Sartori, R., Candiotto, L., Ruggeri, M. & Tagariello, G. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim. Blood Transfus 12 Suppl 1, s151-152, doi:10.2450/2013.0135-13 (2014).
Scaramucci, L. et al. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfus 12, 605-607, doi:10.2450/2014.0246.13 (2014).
Gonzalez-Porras, J. R. et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 169, 111-116, doi:10.1111/bjh.13266 (2015).
Kuter, D. J. et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. International journal of hematology 101, 255-263, doi:10.1007/s12185-014-1731-7 (2015).
Piccin, A., Amaddii, G., Natolino, F., Billio, A. & Cortelazzo, S. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Blood Transfus 12 Suppl 1, s149-150, doi:10.2450/2013.0289-12 (2014).
U.S. Food and Drug Administration. Guidance for industry: Product development under the Animal Rule. (2015).
Ghosh, S. P. et al. Gamma tocotrienol modulates radiation-induced microRNA expression in mouse spleen Radiation Research, accepted for publication. (2016).
Kumar, V. P. et al. PEGylated IL-11 (BBT-059): A Novel Radiation Countermeasure for Hematopoietic Acute Radiation Syndrome. Health Phys 115, 65-76, doi:10.1097/HP.0000000000000841 (2018).
Sharma, N. K. et al. Delayed effects of acute whole body lethal radiation exposure in mice pre-treated with BBT-059. Sci Rep 10, 6825, doi:10.1038/s41598-020-63818-7 (2020).

Competing interest reported. The following authors (VPK, GPHH, SS, SB, NKS, BH, CD and SPG) declare no conflict of interest. MG and GE are employees of Johnson & Johnson and its subsidiary Janssen Pharmaceuticals is working on the development of JNJ-26366821 and stand to benefit financially from the successful development of the compound.

SupplementaryInformation.pdf

Download PDF

Journal Publication

published 03 Mar, 2022

Read the published version in Scientific Reports →

Editorial decision: Major revision
20 Dec, 2021
Reviews received at journal
19 Dec, 2021
Reviewers agreed at journal
10 Dec, 2021
Reviewers invited by journal
10 Dec, 2021
Editor assigned by journal
10 Dec, 2021
Editor invited by journal
10 Dec, 2021
Submission checks completed at journal
10 Dec, 2021
First submitted to journal
01 Dec, 2021

You are reading this latest preprint version

Mitigation of Total Body Irradiation-Induced Mortality and Hematopoietic Injury of Mice by a Thrombopoietin Mimetic (JNJ-26366821)

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Results

JNJ-26366821 administered 4-24 hours post-TBI increases survival

JNJ-26366821 dose-dependently enhances survival post-TBI

JNJ-26366821 enhances survival up to 24 hours post-TBI

JNJ-26366821 administered 24 hours post-TBI enhances recovery of neutrophils, platelets, and bone marrow progenitor cells

JNJ-26366821 enhances survival and hematopoietic recovery in an additional mouse strain

Discussion

Conclusion

Materials And Methods

Animals

Drug and drug preparation

Total Body Irradiation (TBI) Studies

Housing and care of animals after irradiation

Survival studies with JNJ-26366821 in CD2F1 and C57/BL6 mice

Dose and time optimization study with JNJ-26366821 in CD2F1 male mice

Hematology studies with JNJ-26366821

FLT3-L determination in serum by ELISA

Colony Forming Unit Assay from Femoral Bone Marrow

Megakaryocytes from Sternal bone marrow

Determination of Dose Reduction Factor (DRF)/long term survival

Statistical analysis

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1